ICER 2023: Circular targets remain out of reach The Netherlands aims to have a fully circular economy by 2050 and halve its use of raw materials by 2030. In recent years, however, little progress has been made in either regard.
Urgent need for more research into environmental effects of microplastics Additional solutions are urgently needed to limit emissions of microplastics into the environment. Growing quantities of microplastics (particles of 5 mm or less) are entering our living environment every day.
Circular economy: plastics recycling from end-of-life vehicles could be four times higher At present, 85% of plastics from end-of-life vehicles is still incinerated. Only 15% of plastics is reused as a raw material. A survey conducted by RIVM has revealed possibilities to expand recovery of these plastics fourfold by 2030.
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Vaccination turnout for people aged 25-44: 66% vaccinated at least once The 26th RIVM vaccination update now shows vaccination turnout for people aged 25-44 years by municipality. This involves people who have received at least one COVID-19 vaccination.
More attention needs to be paid to the safe recycling of waste According to the National Institute for Public Health and the Environment (RIVM) there needs to be a greater (international) focus on, and increased awareness of, the safe recycling of waste.
Heterologous vaccination from 16 July on Following an advisory report by the Health Council, Minister De Jonge decided on 6 July 2021, effective as of 16 July, that people who had received one vaccination with AstraZeneca could opt for the Pfizer/BioNTech for their second jab.
Vaccination coverage is rising, while data is increasingly comprehensive The RIVM vaccination update this week has been expanded to include vaccination coverage by municipality, specifying full COVID-19 vaccination among people aged 65 and over and people aged 45-64 years.
Long COVID also possible after a mild case: interim research results More than 95% of the 1,741 participants in RIVM’s LongCOVID study, who reported long-term symptoms after COVID-19, had mild symptoms during the acute phase of the infection.